Chiltern Int expands in Portugal

30 April 2006

UK-headquartered contract research group Chiltern International says that it has increased its presence in Portugal as the country rises in prominence as a location for clinical trials.

To improve coordination of activities in the country, Chiltern International Portugal Lda has been established. The new set up provides a structure that will enable the firm to deal with international Portuguese work on a more national basis, it says.

Ricardo Diaz, who has become clinical operations manager for Portugal, commented: "we have extremely motivated personnel who are keen to promote the growth of our company in Portugal. The European Directive has been successfully implemented and this should help the clinical trial environment in the European Union."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight